Ticker Details
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
IPO Date:	July 24, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$121.15B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.87 | 1.66%
Avg Daily Range (30 D):	$6.24 | 1.34%
Avg Daily Range (90 D):	$5.30 | 1.18%

Institutional Daily Volume
Avg Daily Volume:	1.59M
Avg Daily Volume (30 D):	1.18M
Avg Daily Volume (90 D):	1.06M

Trade Size
Avg Trade Size (Sh.):	91
Avg Trade Size (Sh.) (30 D):	28
Avg Trade Size (Sh.) (90 D):	26

Institutional Trades
Total Institutional Trades:	30,431
Avg Institutional Trade:	$8.82M
Avg Institutional Trade (30 D):	$40.76M
Avg Institutional Trade (90 D):	$41.32M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$32.6M
Avg Closing Trade (30 D):	$115.57M
Avg Closing Trade (90 D):	$114.04M
Avg Closing Volume:	146.68K

News

Feb 24, 2026 @ 8:30 AM The Ultimate Biotech Stock to Buy With $500 Right ... Source: Adria Cimino

Feb 22, 2026 @ 11:30 PM Could Vertex Stock Help Turn $100,000 Into $1 Mill... Source: Prosper Junior Bakiny

Feb 20, 2026 @ 3:22 PM CRISPR Therapeutics Gains After Earnings as Pipeli... Source: Chris Markoch

Feb 13, 2026 @ 8:10 PM The Blastoff-Ready Biotech Stock You'll Kick Yours... Source: Adria Cimino

Feb 13, 2026 @ 6:48 PM Small Caps, Silver Rally As Inflation Cools Furthe... Source: Piero Cingari

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$15.46	$4.69	$15.46
Diluted EPS	$15.32	$4.64	$15.32
Revenue	$12B	$3.19B	$12B
Gross Profit	$10.35B	$2.72B	$10.35B
Net Income / Loss	$3.95B	$1.19B	$3.95B
Operating Income / Loss	$4.17B	$1.21B	$4.17B
Cost of Revenue	$1.65B	$466M	$1.65B
Net Cash Flow	$515.6M	$140M	$515.6M
PE Ratio	31.84

Splits
Aug 24, 2000	2:1